Guy Young/LinkedIn
Jan 2, 2026, 03:50
Emicizumab in Infants: Not Just Cost-effective but Mandatory
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
“Emicizumab in infants: not just cost-effective but mandatory.”
Author: Guy Young
Read the full article.
More posts by Flora Peyvandi on Hemostasis Today.
-
Jul 12, 2026, 20:44Mary Cushman: Starting ISTH 2026 With Women’s Thrombosis and Hemostasis Health
-
Jul 12, 2026, 20:43Elif Güler Kazanci: Honored to Attend ISTH 2026
-
Jul 12, 2026, 20:41Anna Waterhouse: Exciting First Day at the ISTH 2026
-
Jul 12, 2026, 20:39Ghadir Alkarithi: Exploring the Latest Advances at ISTH 2026
-
Jul 12, 2026, 20:21Rainer Kaiser: How T Cells Boost Myeloid Effector Functions in Endocarditis
-
Jul 12, 2026, 17:04Marc Carrier: EPCAT III Trial at ISTH 2026 Supports Aspirin Alone for VTE Prevention After Arthroplasty
-
Jul 12, 2026, 16:15Louise St. Germain Bannon: Global Collaboration Is Key to Turning Scientific Innovation Into Better Care
-
Jul 12, 2026, 16:10Marc Carrier: Major Scientific Highlight Confirms the Safety of the YEARS Algorithm at ISTH 2026
-
Jul 12, 2026, 16:01Joseph R. Shaw: Sharing New Insights into Antithrombotic Therapy and Thrombin Generation at ISTH 2026